This informal session provides the perfect opportunity to build meaningful connections with pharma, biotech, and academic KOLs, exchange insights on translational strategies and trial design, and gain exclusive, first-hand perspectives on the latest breakthroughs in this niche subset of rare and autoimmune-driven diseases.